Thomas A. Comery

6.5k citations

40 papers · 4.6k indexed · 4 hit papers · h-index 20

Cellular and Molecular Neuroscience top 1%
- Neuroscience and Neuropharmacology Research 12
- Neurotransmitter Receptor Influence on Behavior 5
Developmental Neuroscience top 2%
Neurology top 2%
Cognitive Neuroscience top 2%
Biological Psychiatry top 2%
Pharmacology
- Cholinesterase and Neurodegenerative Diseases 14
Molecular Biology
- Receptor Mechanisms and Signaling 11
- Nicotinic Acetylcholine Receptors Study 8
- Phenothiazines and Benzothiazines Synthesis and Activities 5
Organic Chemistry
- Chemical synthesis and alkaloids 6
Physiology
- Alzheimer's disease research and treatments 4

Co-authors: William T. Greenough Scott A. Irwin Ivan Jeanne Weiler Patrick J. Willems Ben A. Oostra Mark R. Bowlby Jeffrey A. Kleim Menelas N. Pangalos
Cited by: Cellular and Molecular Neuroscience Developmental Neuroscience Neurology
Journals: Bioorganic & Medicinal Chemistry Letters (5 papers)Journal of Medicinal Chemistry (5 papers)Alzheimer s & Dementia (4 papers)
Partner nations: United States Canada Italy

In The Last Decade

Thomas A. Comery

39 papers receiving 4.5k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2008 Neuron
2006 Proceedings of the National Academy of Sciences
1997 Proceedings of the National Academy of Sciences
1997 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Thomas A. Comery

Since Specialization

Citations

This map shows the geographic impact of Thomas A. Comery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Comery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Comery more than expected).

Fields of papers citing papers by Thomas A. Comery

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Comery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Comery. The network helps show where Thomas A. Comery may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Thomas A. Comery, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas A. Comery Line = papers co-authored together Thomas A. Comery links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Metabolism of a 5HT6 Antagonist, 2-Methyl-1-(Phenylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzo[d]imidazole (SAM-760): Impact of Sulfonamide Metabolism on Diminution of a Ketoconazole-Mediated Clinical Drug-Drug Interaction Drug Metabolism and Disposition ·Aarti Sawant‐Basak,R. Scott Obach,Angela C. Doran,Peter Lockwood,Klaas Schildknegt,Hongying Gao,Jessica Mancuso,Susanna Tse,Thomas A. Comery	2018	6
2	5-HT2C Agonists as Therapeutics for the Treatment of Schizophrenia Handbook of experimental pharmacology ·Sharon Rosenzweig‐Lipson,Thomas A. Comery,Karen L. Marquis,Jonathan Groß,John Dunlop	2012	37
3	Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625 Psychopharmacology ·Karen L. Marquis,Thomas A. Comery,Flora Jow,Rachel L. Navarra,Steven M. Grauer,Claudine Pulicicchio,Cody Kelley,Julie Brennan,Renza Roncarati,Carla Scali,Simon N. Haydar,Chiara Ghiron,Georg C. Terstappen,John Dunlop	2011	15
4	Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT6 antagonists Bioorganic & Medicinal Chemistry ·Kevin G. Liu,Albert J. Robichaud,XIANG-ZHOU CHEN,Andreĭ Kalpashnikov,Igor Mrnjavčić,James F. Mattes,Yanxuan Cai,Shenqin Leng,R. Dzingel,Dianne Kowal,Deborah L. Smith,Li Di,Edward H. Kerns,Lee E. Schechter,Thomas A. Comery	2010	19
5	SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist Bioorganic & Medicinal Chemistry ·Simon N. Haydar,Chiara Ghiron,Laura Bettinetti,Hendrick Bothmann,Thomas A. Comery,John Dunlop,Salvatore La Rosa,英喜斎藤,G.P. Gravlee,杨贞树,Renza Roncarati,Carla Scali,Michela Valacchi,M. Varrone,Riccardo Zanaletti	2009	36
6	Procognitive and Neuroprotective Activity of a Novel α7 Nicotinic Acetylcholine Receptor Agonist for Treatment of Neurodegenerative and Cognitive Disorders Journal of Pharmacology and Experimental Therapeutics ·Renza Roncarati,Carla Scali,Thomas A. Comery,Steven M. Grauer,Wijewardane Abeywickrama Nishshanka,Hendrick Bothmann,Brian Jow,Dianne Kowal,Marco Gianfriddo,Cody Kelley,Ugo Zanelli,Chiara Ghiron,Simon N. Haydar,John Dunlop,Georg C. Terstappen	2009	88
7	The supra-additive hyperactivity caused by an amphetamine–chlordiazepoxide mixture exhibits an inverted-U dose response: Negative implications for the use of a model in screening for mood stabilizers Pharmacology Biochemistry and Behavior ·Michy P. Kelly,Sheree F. Logue,Jason M. Dwyer,Chad E. Beyer,Kellyn Madden,Cai Zhang,Zhi Liu,Adedayo Adedoyin,Sharon Rosenzweig‐Lipson,Thomas A. Comery	2009	18
8	Identification of a novel series of 3-piperidinyl-5-sulfonylindazoles as potent 5-HT6 ligands Bioorganic & Medicinal Chemistry Letters ·Kevin G. Liu,Andreĭ Kalpashnikov,Thomas A. Comery,Shenqin Leng,R. Dzingel,Dianne Kowal,Deborah L. Smith,Li Di,Edward H. Kerns,Lee E. Schechter,Albert J. Robichaud	2009	9
9	A cog in cognition: How the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits Pharmacology & Therapeutics ·Steven C. Leiser,Mark R. Bowlby,Thomas A. Comery,John Dunlop	2009	136
10	Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia Journal of Pharmacology and Experimental Therapeutics ·Steven M. Grauer,Virginia Pulito,Rachel L. Navarra,Michy P. Kelly,Cody Kelley,Radka Graf,Barbara Langen,Sheree F. Logue,Julie Brennan,Lixin Jiang,Erik I. Charych,Ute Egerland,Feng Liu,Karen L. Marquis,Michael S. Malamas,Thorsten Hage,Thomas A. Comery,Nicholas J. Brandon	2009	223
11	Identification of a series of benzoxazoles as potent 5-HT6 ligands Bioorganic & Medicinal Chemistry Letters ·Kevin G. Liu,Andreĭ Kalpashnikov,Thomas A. Comery,Shenqin Leng,R. Dzingel,Dianne Kowal,Deborah L. Smith,Li Di,Edward H. Kerns,Lee E. Schechter,Albert J. Robichaud	2009	51
12	ApoE Promotes the Proteolytic Degradation of Aβbreakdown → Neuron ·Qingguang Jiang,Willard F. Reese,Shweta Mandrekar,Brandy Wilkinson,Paige E. Cramer,Noam Zelcer,Karen M. Mann,Bruce T. Lamb,Timothy M. Willson,Jon L. Collins,Jill Richardson,Jonathan D. Smith,Thomas A. Comery,David Riddell,David M. Holtzman,Peter Tontonoz,Gary E. Landreth	2008	716
13	WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics Psychopharmacology ·Steven M. Grauer,Radka Graf,Rachel L. Navarra,Amy Sung,Sheree F. Logue,Gary Stack,Christine Huselton,Zhi Liu,Thomas A. Comery,Karen L. Marquis,Sharon Rosenzweig‐Lipson	2008	18
14	Old and New Pharmacology: Positive Allosteric Modulation of the α7 Nicotinic Acetylcholine Receptor by the 5-Hydroxytryptamine2B/C Receptor Antagonist SB-206553 (3,5-Dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b′]di pyrrole-1(2 H)-carboxamide) Journal of Pharmacology and Experimental Therapeutics ·John Dunlop,G. Stöger,Brian Jow,Socayna Jouide,Steven M. Grauer,Flora Jow,Angela Krämer,Mark R. Bowlby,Andrew D. Randall,Dianne Kowal,A. Gilbert,Thomas A. Comery,James LaRocque,Veronica Soloveva,Jon T. Brown,Renza Roncarati	2008	56
15	Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test Progress in Neuro-Psychopharmacology and Biological Psychiatry ·Rachel L. Navarra,Radka Graf,Youping Huang,Sheree F. Logue,Thomas A. Comery,Zoë A. Hughes,Mark L. Day	2007	149
16	Acute γ-Secretase Inhibition Improves Contextual Fear Conditioning in the Tg2576 Mouse Model of Alzheimer's Disease Journal of Neuroscience ·Thomas A. Comery,Robert Martone,Suzan Aschmies,Kevin Atchison,George Diamantidis,Xiaohai Gong,Hua Zhou,Anthony F. Kreft,Menelas N. Pangalos,June Sonnenberg‐Reines,J. Steven Jacobsen,Karen L. Marquis	2005	176
17	Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activationbreakdown → Proceedings of the National Academy of Sciences ·Ivan Jeanne Weiler,Scott A. Irwin,Anna Y. Klintsova,Corinne M. Spencer,Gauri Mittal,Kevin Miyashiro,Thomas A. Comery,Bindu Patel,James Eberwine,William T. Greenough	1997	530
18	Synaptogenesis and FOS Expression in the Motor Cortex of the Adult Rat after Motor Skill Learning Journal of Neuroscience ·Jeffrey A. Kleim,Max Nitze,Adrian Olivera,Thomas A. Comery,William T. Greenough	1996	432
19	Increased Density of Multiple-Head Dendritic Spines on Medium-Sized Spiny Neurons of the Striatum in Rats Reared in a Complex Environment Neurobiology of Learning and Memory ·Thomas A. Comery,Sa-Young Park,Scott A. Irwin,William T. Greenough	1996	119
20	Differential Rearing Alters Spine Density on Medium-Sized Spiny Neurons in the Rat Corpus Striatum: Evidence for Association of Morphological Plasticity with Early Response Gene Expression Neurobiology of Learning and Memory ·Thomas A. Comery,Rachna Shah,William T. Greenough	1995	89

About Thomas A. Comery

Thomas A. Comery is a scholar working on Pharmacology, Cellular and Molecular Neuroscience, Biological Psychiatry, Organic Chemistry and Cognitive Neuroscience, having authored 40 papers that have together received 4.6k indexed citations. Recurring topics across this work include Cholinesterase and Neurodegenerative Diseases (14 papers), Neuroscience and Neuropharmacology Research (12 papers), Receptor Mechanisms and Signaling (11 papers), Nicotinic Acetylcholine Receptors Study (8 papers), Chemical synthesis and alkaloids (6 papers), Phenothiazines and Benzothiazines Synthesis and Activities (5 papers), Neurotransmitter Receptor Influence on Behavior (5 papers) and Alzheimer's disease research and treatments (4 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (1.5k citations), Developmental Neuroscience (302 citations), Neurology (520 citations), Cognitive Neuroscience (1.1k citations) and Biological Psychiatry (147 citations). Thomas A. Comery has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include William T. Greenough, Scott A. Irwin, Ivan Jeanne Weiler, Patrick J. Willems, Ben A. Oostra, Mark R. Bowlby, Jeffrey A. Kleim, Menelas N. Pangalos, J. Steven Jacobsen and Robert Martone. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Alzheimer s & Dementia, Journal of Pharmacology and Experimental Therapeutics and Journal of Neuroscience.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact